A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction.
Int. J. Cardiol., Dec (2012)
A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat.
PLoS ONE., 7(10):e47160 (2012)
Cell therapy for diabetic nephropathy: is the future, now?
Semin. Nephrol., Sep;32(5):486-93 (2012)
Early and Delayed Tranilast Treatment Reduces Pathological Fibrosis Following Myocardial Infarction.
Heart Lung Circ., Sep (2012)
Hyperglycemia and renal mass ablation synergistically augment albuminuria in the diabetic subtotally nephrectomized rat: implications for modeling diabetic nephropathy.
Nephron Extra., Jan;2(1):115-24 (2012)
Can Fam Physician., Jun;58(6):634-6 (2012)
Bone marrow cell therapies for endothelial repair and their relevance to kidney disease.
Semin. Nephrol., Mar;32(2):215-23 (2012)
The endothelium in diabetic nephropathy.
Semin. Nephrol., Mar;32(2):199-207 (2012)
Early-outgrowth bone marrow cells attenuate renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetes.
Diabetes., Aug;61(8):2114-25 (2012)
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.
Can J Cardiol., May;28(3):270-87 (2012)
FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy.
Eur. J. Heart Fail., May;14(5):549-62 (2012)
The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice.
J. Clin. Invest., Feb;122(2):759-76 (2012)
Fluorescent microangiography is a novel and widely applicable technique for delineating the renal microvasculature.
PLoS ONE., 6(10):e24695 (2011)
Hypertension in people with type 2 diabetes: Update on pharmacologic management.
Can Fam Physician., Sep;57(9):997-1002, e347-53 (2011)
Combination Angiotensin Converting Enzyme and Direct Renin Inhibition in Heart Failure following Experimental Myocardial Infarction.
Cardiovasc Ther., Jul (2011)
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.
Can J Cardiol., 27(4):415-433.e1-2 (2011 Jul-Aug)
Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart.
Clin. Exp. Pharmacol. Physiol., Sep;38(9):623-31 (2011)
Protein kinase C Î² inhibition ameliorates experimental mesangial proliferative glomerulonephritis.
Nephrology (Carlton)., Sep;16(7):649-55 (2011)
Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism.
Am. J. Pathol., May;178(5):2205-14 (2011)
The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy.
J. Hypertens., Jun;29(6):1175-84 (2011)